Amgen (AMGN) Other Non-Current Liabilities (2009 - 2026)
Amgen (AMGN) posted quarterly Other Non-Current Liabilities of $2.4 billion for Q1 2026, up 7.01% year-over-year from $2.2 billion in Q1 2025, and down 0.55% quarter-over-quarter from $2.4 billion in Q4 2025.
Amgen (AMGN) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Amgen's Other Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $2.4 billion for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 7.01% year-over-year to $2.4 billion; the TTM figure through Mar 2026 stood at $2.4 billion (up 7.01% YoY), while the FY2025 annual figure was $2.4 billion, up 1.23% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $2.4 billion, down from $2.4 billion in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $5.6 billion in Q2 2022, with the low at $96.0 million in Q1 2024.
- The 5-year median for Other Non-Current Liabilities is $2.3 billion (2025), against an average of $2.0 billion.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities slumped 96.59% in 2023, then jumped 2226.53% in 2024.
- Amgen's Other Non-Current Liabilities stood at $270.0 million in 2022, then surged by 1633.33% to $4.7 billion in 2023, then slumped by 49.81% to $2.3 billion in 2024, then grew by 1.23% to $2.4 billion in 2025, then declined by 0.55% to $2.4 billion in 2026.
- Business Quant data shows AMGN's Other Non-Current Liabilities at $2.4 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.84 Bn |
| Mar 31, 2026 | 2.37 Bn |
| Dec 31, 2025 | 2.38 Bn |
| Sep 30, 2025 | 2.62 Bn |
| Jun 30, 2025 | 2.34 Bn |
| Mar 31, 2025 | 2.21 Bn |
| Dec 31, 2024 | 2.35 Bn |
| Sep 30, 2024 | 2.28 Bn |
| Jun 30, 2024 | 107.00 Mn |
| Mar 31, 2024 | 96.00 Mn |
| Dec 31, 2023 | 4.68 Bn |
| Sep 30, 2023 | 98.00 Mn |
| Jun 30, 2023 | 248.00 Mn |
| Mar 31, 2023 | 273.00 Mn |
| Dec 31, 2022 | 270.00 Mn |
| Sep 30, 2022 | 2.88 Bn |
| Jun 30, 2022 | 5.60 Bn |
| Mar 31, 2022 | 2.73 Bn |
| Dec 31, 2021 | 342.00 Mn |
| Sep 30, 2021 | 2.16 Bn |